| Assessment Status |
Assessment Process Complete |
| HTA ID |
- |
| Drug |
Ramucirumab |
| Brand |
Cyramza® |
| Indication |
In combination with paclitaxel for the treatment of adult patients with advanced GC or gastro oesophageal junction (GEJ) adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy and as monotherapy for the treatment of adult patients with advanced GC or GEJ adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate. |
| Rapid review commissioned |
20/12/2014 |
| Rapid review completed |
23/12/2014 |
| Rapid review outcome |
Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant |
03/12/2015 |
| NCPE assessment completed |
26/07/2016 |
| NCPE assessment outcome |
Reimbursement Not Recommended at the Submitted Price. |
